Antivirals: Global Anti-Infectives Markets Vol. I

SUMMARY

Antiviral drugs are the main, if only, method of treatment of major viral disease conditions. This Theta Report is the first in a three-volumeseries of market research reports on global anti-infective drug markets.

In order to recognize the opportunities presented by the antiviral pharmaceuticals market, companies need to be aware of treatment advances, aswell as probable future offerings and their projected impact on future drug sales. This report presents global market analysis by geographic regionand by major drug products, as well as competitive positions of major players and competitive dynamics affecting market change.

Major viral disease conditions for which antivirals are used as in this report are:

• Hepatitis B
• Hepatitis C
• Human immunodeficiency virus (HIV)
• Herpes virus
• Influenza
• Respiratory syncytial virus (RSV)
• Human papillomavirus (HPV)

Classes of antiviral drugs discussed include:

• Interferons
• Nucleoside reverse transcriptase inhibitors (NRTIs)
• Non-nucleoside reverse transcriptase inhibitors (nNRTIs)
• Protease inhibitors
• Other drugs: anti-influenza agents, neuraminidase inhibitors, immunoglobulins, immunomodulators

An essential strategic resource, Theta' s Antivirals: Global Anti-Infectives

Markets Vol. I answers the following questions:

• What conditions currently require treatment with antivirals?
• What are the healthcare costs of these conditions?
• Why are these conditions such a problem?
• What antiviral products are currently available to treat these conditions?
• What antiviral products are currently in development for these conditions?
• What are the current market sizes and forecasted market projections for antiviral drugs for each condition, based on drug class/product andgeographic region?
• Who are the major competitors and what are their current market shares?

TABLE OF CONTENTS

1 Executive Summary

1.1 Scope and Objectives of the Report

1.2 Methodology

2 Introduction and Overview

2.1 Definition of Antiviral Drugs

2.2 Classes of Antiviral Drugs

2.2.1 Interferons

2.2.2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

2.2.3 Non-Nucleoside Reverse Transcriptase Inhibitors (nNRTIs)

2.2.4 Protease Inhibitors

2.3 Disease Conditions for Use

2.4 Prevalence and Demographics

3 Issues and Trends in Antivirals

3.1 Health and Economic Consequences

3.2 Legislative and Industry Actions Impacting Antivirals

3.3 Medical and Development Issues

3.3.1 Antiviral Drug Resistance

3.3.2 Patent Expirations

3.4 Severe Acute Respiratory Syndrome (SARS)

3.4.1 A New Viral Condition

3.4.2 Drugs and Diagnostics in Development

4 Hepatitis B

4.1 Overview of Condition

4.1.1 Risk Factors

4.1.2 Incidence/Mortality

4.1.3 Diagnostics

4.2 Treatments

4.2.1 INTRON A

4.2.2 Epivir-HBV/Zeffix

4.2.3 Hepsera

4.3 Research and Development

4.4 Global Market Analysis

4.4.1 Total World Market Size and Growth

4.4.2 U.S. Market Size and Growth

4.4.3 Western European Market Size and Growth

4.4.4 Japanese Market Size and Growth

4.4.5 Rest of World Market Size and Growth

4.5 Competitor Analysis

5 Hepatitis C

5.1 Overview of Condition

5.1.1 Risk Factors

5.1.2 Incidence/Mortality

5.1.3 Diagnostics

5.2 Treatments

5.2.1 INTRON A

5.2.2 Roferon A

5.2.3 Infergen

5.2.4 PEG-Intron

5.2.5 Pegasys

5.2.6 Rebetron

5.2.7 Rebetol

5.2.8 Copegus

5.3 Research and Development

5.4 Global Market Analysis

5.4.1 Total World Market Size and Growth

5.4.2 U.S. Market Size and Growth

5.4.3 Western European Market Size and Growth

5.4.4 Japanese Market Size and Growth

5.4.5 Rest of World Market Size and Growth

5.5 Competitor Analysis

6 Human Immunodeficiency Virus (HIV)

6.1 Overview of Condition

6.1.1 Risk Factors

6.1.2 Incidence/Mortality

6.1.3 Diagnostics

6.2 Treatments

6.2.1 Fortovase/Invirase

6.2.2 Norvir

6.2.3 Crixivan

6.2.4 Viracept

6.2.5 Agenerase

6.2.6 Kaletra

6.2.7 Reyataz

6.2.8 Retrovir/AZT

6.2.9 Epivir

6.2.10 Combivir

6.2.11 Hivid

6.2.12 Videx

6.2.13 Trizivir

6.2.14 Zerit

6.2.15 Ziagen

6.2.16 Viread

6.2.17 Viramune

6.2.18 Rescriptor

6.2.19 Sustiva

6.3 Research and Development

6.4 Global Market Analysis

6.4.1 Total World Market Size and Growth

6.4.2 U.S. Market Size and Growth

6.4.3 Western European Market Size and Growth

6.4.4 Japanese Market Size and Growth

6.4.5 Rest of World Market Size and Growth

6.5 Competitor Analysis

7 Herpes Simplex Virus

7.1 Overview of Conditions

7.1.1 Risk Factors

7.1.2 Incidence/Mortality

7.1.3 Diagnostics

7.2 Treatments

7.2.1 Valtrex

7.2.2 Famvir

7.2.3 Zovirax

7.2.4 Natural Products

7.3 Research and Development

7.4 Global Market Analysis

7.4.1 Total World Market Size and Growth

7.4.2 U.S. Market Size and Growth

7.4.3 Western European Market Size and Growth

7.4.4 Japanese Market Size and Growth

7.4.5 Rest of World Market Size and Growth

7.5 Competitor Analysis

8 Other: Influenza, RSV, HPV

8.1 Overview of Conditions

8.1.1 Risk Factors

8.1.2 Incidence/Mortality

8.1.3 Diagnostics

8.2 Treatments

8.2.1 Tamiflu

8.2.2 Relenza

8.2.3 Amantadine and Rimantadine

8.2.4 Ribavirin

8.2.5 Aldara

8.2.6 Condylox

8.3 Research and Development

8.4 Global Market Analysis

8.4.1 Total World Market Size and Growth

8.4.2 U.S. Market Size and Growth

8.4.3 Western European Market Size and Growth

8.4.4 Japanese Market Size and Growth

8.4.5 Rest of World Market Size and Growth

8.5 Competitor Analysis

9 Overall Market Summary

9.1 Total World Market Size: 2002, 2008

9.2 World Markets by Viral Condition: 2002, 2008

9.3 World Markets by Geographic Region: 2002, 2008

10 Company Briefs

10.1 Abbott Laboratories

10.2 Boehringer Ingelheim GmbH

10.3 Bristol-Myers Squibb

10.4 GlaxoSmithKline plc

10.5 MedImmune Inc.

10.6 Merck & Co., Inc.

10.7 3M

10.8 Pfizer Inc.

10.9 F. Hoffmann-La Roche & Co.

10.10 Schering-Plough Corp.

List of Tables

Table 2-1 Prevalence of Viral Diseases by Type & Geographic Region.

Table 4-1 Major Antivirals for Hepatitis B

Table 4-2 Antivirals in Development for Hepatitis B.

Table 4-3 World Market Size and Growth for Hepatitis B Antivirals by Drug Product 2002, 2008

Table 4-4 World Market Size and Growth for Hepatitis B Antivirals by Geographic Region 2002, 2008

Table 4-5 U.S. Market Size for Hepatitis B Antivirals by Drug Product 2002, 2008

Table 4-6 Western European Market Size for Hepatitis B Antivirals by Drug Product 2002, 2008

Table 4-7 Japanese Market Size for Hepatitis B Antivirals by Drug Product 2002, 2008

Table 4-8 Rest of World Market Size for Hepatitis B Antivirals by Drug Product 2002, 2008

Table 4-9 Competitor Revenues and World Market Shares for Hepatitis B Antivirals 2002

Table 5-1 Major Antivirals for Hepatitis C

Table 5-2 Antivirals in Development for Hepatitis C.

Table 5-3 World Market Size and Growth for Hepatitis C Antivirals by Drug Class 2002, 2008

Table 5-4 World Market Size and Growth for Hepatitis C Antivirals

by Geographic Region 2002, 2008

Table 5-5 U.S. Market Size for Hepatitis C Antivirals by Drug Class 2002, 2008

Table 5-6 Western European Market Size for Hepatitis C Antivirals by Drug Class 2002, 2008

Table 5-7 Japanese Market Size for Hepatitis C Antivirals by Drug Class 2002, 2008.

Table 5-8 Rest of World Market Size for Hepatitis C Antivirals by Drug Class 2002, 2008

Table 5-9 Competitor Revenues and World Market Shares for Hepatitis C Antivirals 2002

Table 6-1 Major Antivirals for HIV

Table 6-2 Antivirals in Development for HIV

Table 6-3 World Market Size and Growth for HIV Antivirals by Drug Class 2002, 2008

Table 6-4 World Market Size and Growth for HIV Antivirals by Geographic Region 2002, 2008

Table 6-5 U.S. Market Size for HIV Antivirals by Drug Class 2002, 2008

Table 6-6 Western European Market Size for HIV Antivirals by Drug Class 2002, 2008

Table 6-7 Japanese Market Size for HIV Antivirals by Drug Class 2002, 2008

Table 6-8 Rest of World Market Size for HIV Antivirals by Drug Class 2002, 2008

Table 6-9 Competitor Revenues and World Market Shares for HIV Antivirals 2002 .

Table 7-1 Major Antivirals for Herpes Simplex Virus

Table 7-2 Natural Treatment Products for Herpes

Table 7-3 World Market Size and Growth for Herpes Antivirals by Drug Product 2002, 2008

Table 7-4 World Market Size and Growth for Herpes Antivirals by Geographic Region 2002, 2008

Table 7-5 U.S. Market Size for Herpes Antivirals by Drug Product 2002, 2008

Table 7-6 Western European Market Size for Herpes Antivirals by Drug Product 2002, 2008

Table 7-7 Japanese Market Size for Herpes Antivirals by Drug Product 2002, 2008

Table 7-8 Rest of World Market Size for Herpes Antivirals by Drug Product 2002, 2008

Table 7-9 Competitor Revenues and World Market Shares for Herpes Antivirals 2002

Table 8-1 Major Antivirals for Influenza.

Table 8-2 Major Antivirals for RSV

Table 8-3 Major Antivirals for HPV

Table 8-4 World Market Size and Growth for Antivirals for Influenza, RSV, and HPV 2002, 2008.

Table 8-5 World Market Size and Growth for Antivirals

for Influenza, RSV, and HPV (Combined) by Geographic Region 2002, 2008

Table 8-6 U.S. Market Size for Antivirals for Influenza, RSV, and HPV 2002, 2008.

Table 8-7 Western European Market Size for Antivirals for Influenza, RSV, and HPV 2002, 2008.

Table 8-8 Japanese Market Size for Antivirals for Influenza, RSV, and HPV 2002, 2008.

Table 8-9 Rest of World Market Size for Antivirals for Influenza, RSV, and HPV 2002, 2008.

Table 8-10 Competitor Revenues and World Market Shares for Antivirals for Influenza, RSV, and HPV (Combined) 2002.

Table 9-1 World Market Size for Antivirals by Viral Condition 2002, 2008

Table 9-2 World Market Size for Antivirals by Geographic Region 2002, 2008

List of Figures

Figure 4-1 World Market Size for Hepatitis B Antivirals by Drug Product 2002, 2008

Figure 4-2 World Market Size for Hepatitis B Antivirals by Geographic Region 2002, 2008

Figure 4-3 U.S. Market Size for Hepatitis B Antivirals by Drug Product 2002, 2008

Figure 4-4 Western European Market Size for Hepatitis B Antivirals by Drug Product 2002, 2008

Figure 4-5 Japanese Market Size for Hepatitis B Antivirals by Drug Product 2002, 2008

Figure 4-6 Rest of World Market Size for Hepatitis B Antivirals by Drug Product 2002, 2008.

Figure 4-7 Competitor World Market Shares for Hepatitis B Antivirals 2002.

Figure 5-1 World Market Size for Hepatitis C Antivirals by Drug Class 2002, 2008

Figure 5-2 World Market Size for Hepatitis C Antivirals by Geographic Region 2002, 2008

Figure 5-3 U.S. Market Size for Hepatitis C Antivirals by Drug Class 2002, 2008

Figure 5-4 Western European Market Size for Hepatitis C Antivirals by Drug Class 2002, 2008

Figure 5-5 Japanese Market Size for Hepatitis C Antivirals by Drug Class 2002, 2008

Figure 5-6 Rest of World Market Size for Hepatitis C Antivirals by Drug Class 2002, 2008

Figure 5-7 Competitor World Market Shares for Hepatitis C Antivirals 2002.

Figure 6-1 World Market Size for HIV Antivirals by Drug Class 2002, 2008

Figure 6-2 World Market Size for HIV Antivirals by Geographic Region 2002, 2008

Figure 6-3 U.S. Market Size for HIV Antivirals by Drug Class 2002, 2008.

Figure 6-4 Western European Market Size for HIV Antivirals by Drug Class 2002, 2008.

Figure 6-5 Japanese Market Size for HIV Antivirals by Drug Class 2002, 2008

Figure 6-6 Rest of World Market Size for HIV Antivirals by Drug Class 2002, 2008

Figure 6-7 Competitor World Market Shares for HIV Antivirals 2002.

Figure 7-1 World Market Size for Herpes Antivirals by Drug Product 2002, 2008

Figure 7-2 World Market Size for Herpes Antivirals by Geographic Region 2002, 2008.

Figure 7-3 U.S. Market Size for Herpes Antivirals by Drug Product 2002, 2008

Figure 7-4 Western European Market Size for Herpes Antivirals by Drug Product 2002, 2008

Figure 7-5 Japanese Market Size for Herpes Antivirals by Drug Product 2002, 2008

Figure 7-6 Rest of World Market Size for Herpes Antivirals by Drug Product 2002, 2008

Figure 7-7 Competitor World Market Shares for Herpes Antivirals 2002

Figure 8-1 World Market Size for Antivirals for Influenza, RSV, and HPV 2002, 2008

Figure 8-2 World Market Size for Antivirals for Influenza, RSV, and HPV (Combined) by Geographic Region 2002, 2008

Figure 8-3 U.S. Market Size for Antivirals for Influenza, RSV, and HPV 2002, 2008

Figure 8-4 Western European Market Size for Antivirals for Influenza, RSV, and HPV 2002, 2008.

Figure 8-5 Japanese Market Size for Antivirals for Influenza, RSV, and HPV 2002, 2008

Figure 8-6 Rest of World Market Size for Antivirals for Influenza, RSV, and HPV 2002, 2008

Figure 8-7 Competitor World Market Shares for Antivirals for Influenza, RSV, and HPV (Combined) 2002 .

Figure 9-1 World Market Size for Antivirals by Viral Condition 2002, 2008

Figure 9-2 World Market Size for Antivirals by Geographic Region 2002, 2008.